GSK plc reported positive phase III results for Nucala (mepolizumab) in treating COPD, showing a significant reduction in severe exacerbations compared to placebo in a trial up to 104 weeks. This filing is significant as it could lead to future regulatory discussions for Nucala's approval in COPD, impacting a condition affecting over 300 million people worldwide.